Is Exelixis Stock (EXEL) Halal? Current Quantitative Sharia Screen

The Short Answer

Exelixis (EXEL) is doubtful on the current examined asset-based financial screens, despite its generally permissible oncology-pharmaceutical activity. The March 31, 2026 filing reports no interest-bearing debt, but marketable securities equal 55.00% of total assets, above the examined 33% liquidity limits. This is a methodology-based result, not a fatwa or universal certification.

This is a reproducible ZakatInvest calculation from Exelixis' March 31, 2026 Form 10-Q. Market-cap denominator methods are not estimated without a licensed historical market-cap series, and the qualitative analysis remains separate from the numerical result.

Sharia Screening Methodology

Islamic equity screens commonly examine:

• Business activity: whether core activity and material revenue streams are permissible
• Debt and liquidity: interest-bearing liabilities and cash or interest-bearing securities relative to assets or market value
• Receivables: receivables plus cash relative to assets, with thresholds varying by methodology
• Non-compliant income: separately disclosed interest or other prohibited income, where the filing permits a reproducible numerator

Exelixis' Business Activity

Exelixis operates one reportable segment focused on discovering, developing and commercializing medicines for difficult-to-treat cancers. Its cabozantinib franchise includes Cabometyx and Cometriq indications, while its pipeline includes zanzalintinib, XB002 and other small-molecule and antibody-drug-conjugate assets. Commercialization and development collaborations include Ipsen, Takeda and Genentech/Roche.

Pharmaceutical research, development and commercialization are generally permissible at the activity level. The Q1 filing reports $610.812 million of revenue, but it does not provide a universal prohibited-revenue numerator by indication, customer, ingredient or end use. No unsupported haram-revenue percentage is therefore estimated.

Qualitative Concerns

1. Marketable-securities liquidity

Exelixis held $1,200.199 million of marketable securities in addition to $226.152 million of cash. The securities include commercial paper, corporate bonds, U.S. government-sponsored securities, municipal bonds, money-market funds and certificates of deposit. The portfolio creates the current quantitative liquidity failure even though no interest-bearing debt is reported.

2. Interest income and purification

Exelixis reported $16.127 million of interest income, or 2.64% of quarterly revenue. That is below the examined 5% income threshold, but no fixed scholar-approved purification rate is asserted. Investors should follow the qualified scholar or methodology they use.

3. Cabozantinib concentration

Cabozantinib products account for most current revenue. Patent-cycle, competition and pipeline execution risks can change the business and financial profile independently of the current Sharia calculation.

4. Collaborations, trials and research

License, royalty and collaboration revenues involve multiple pharmaceutical partners. Clinical-trial outcomes, regulatory approvals, animal-derived research materials and product-access debates are appropriate qualitative diligence topics; none is silently converted into a fabricated prohibited-revenue percentage.

Current Financial Ratios (March 31, 2026)

• Interest-bearing debt / assets: 0.00% — no reported interest-bearing debt ✅
• Cash + interest-bearing securities / assets: 55.00% — above the examined 33% limits ❌
• Receivables + cash / assets: 21.40% — below the examined 50% limit ✅
• Disclosed interest income / revenue: 2.64% — below the examined 5% threshold ✅
• Prohibited-revenue numerator: Not disclosed; business-activity allocation remains incomplete

How to Read the Result

EXEL is financially failing on the examined asset-based liquidity ratio even though debt, receivables-plus-cash and disclosed interest income pass. The oncology activity is generally permissible, but investors using FTSE Yasaar, MSCI total-assets or Malaysia SAC-style limits should treat the current result as doubtful until a later filing changes the balance-sheet mix.

• FTSE Yasaar asset-based financial screen — Fails at 55.00% liquidity ❌
• MSCI Islamic total-assets financial screen — Fails at 55.00% liquidity ❌
• Malaysia SAC asset-based financial screen — Fails at 55.00% liquidity ❌

Bottom Line

Exelixis (EXEL) is currently doubtful on the examined quantitative screens. Its oncology-pharmaceutical activity is generally permissible and it reports no interest-bearing debt, but the 55.00% marketable-securities liquidity ratio exceeds the examined asset-based limits. Investors should recheck the next filing and consult their preferred Sharia adviser for their own standard.